Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Headlines > Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list

Headlines

Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list

Published by Global Banking and Finance Review

Posted on February 24, 2025

Featured image for article about Headlines

(Reuters) - Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.

(Reporting By Brendan Pierson in New York; Editing by Leslie Adler)

More from Headlines

Explore more articles in the Headlines category

UN, aid groups warn Gaza operations at risk from Israel impediments

IMF says Moldova's economy has unique growth opportunity, but reforms needed

UK firm Awendio Solaris plans $725 million solar plant with indigenous groups in Canada

AbbVie, several other pharma companies near MFN deal with Trump, sources say

US, Russia to hold talks in Miami this weekend, Politico reports

EU reaches initial agreement on tighter EU-Mercosur safeguards

Britain to overhaul benchmark rules to cut industry burden

Novartis, Roche near US drug price deal, Bloomberg News reports

Italy's top court upholds acquittal of Salvini in migrant kidnapping case

Zelenskiy tells Europe: Use frozen assets to end Russia's appetite for war

Sweeping US defense bill passes, with Ukraine, Venezuela provisions defying Trump

Sarajevo takes steps on air quality after most-polluted city ranking

View All Headlines Posts